American Society of Hirudotherapy

Therostasin

Factor Xa inhibitor from Theromyzon tessulatum — Kunitz-domain analog with novel selectivity profile.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Therostasin14 kDa
Molecular weight (kilodaltons) of Therostasin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Therostasin's in vitro inhibition of Factor Xa does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
14,000 Da
Source species
Theromyzon tessulatum
Discovered
1999 · Chopin V et al.

Biological Targets

  • → Factor Xa

Key Citations

  1. Chopin V et al. (2000), J Biol Chem · PMID 10852926

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.